Progression despite transplantion of stem cells

Curro' D, Vuolo L, Gualandi F, Bacigalupo A, Roccatagliata L, Capello E, Uccelli A, Saccardi R, Sormani MP, Mancardi G.
Low intensity lympho-ablative regimen followed by autologous haematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
Mult Scler. 2015 Jan 12. pii: 1352458514564484. [Epub ahead of print]
BACKGROUND:Autologous hematopoietic stem cell transplantation (HSCT) has been successfully used to treat aggressive forms of multiple sclerosis (MS) that are unresponsive to approved therapies. In the last years, in view of the risk of mortality related to the procedure, the utilization of low-intensity conditioning regimens has been considered.
OBJECTIVE:To report magnetic resonance imaging (MRI) and clinical data in a small cohort of patients treated with a low-intensity lympho-ablative regimen, followed by HSCT.
METHODS:Seven patients affected by relapsing-remitting MS (RRMS) underwent HSCT, with cyclophosphamide 120 mg/kg in 2 days as the conditioning regimen; and were then followed with serial MRI evaluations until 36 months, with clinical evaluations until 60 months.
RESULTS: The mean number of gadolinium (Gd)-enhancing lesions significantly decreased after treatment, but a complete suppression of inflammatory activity was not obtained. No deaths occurred, but every patient developed adverse events, although not severe. After 5 years of follow-up, two patients remained stable, one patient markedly improved and four patients had a mild progression of the disease. Only one patient experienced a relapse after treatment.
CONCLUSION: A low-intensity conditioning regimen with HSCT has a profound effect on MRI inflammation and relapses, but is not able to completely abrogate MRI activity and disease progression of aggressive RRMS.

We have shown that a high dose of cyclophosphamide can shut down relapsing EAE. In this study it helps clear out the old immune response. But using a less aggressive treatment then it doesn't get rid of all activity and disease can carry-on. Is this better than some thing like Alemtuzumab?